Using cfDNA and ctDNA as Oncologic Markers: A Path to Clinical ValidationJonathan Dao, Daruka Mahadevan|International Journal of Molecular Sciences|2023Cited by 89
MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancerWenqing Qi, Daruka Mahadevan|BMC Cancer|2009Cited by 56
Phase 2 Randomized Multicenter Study of Extended Dosing Schedules of Oral Ezatiostat HCl (Telintra), a Glutathione Analog Prodrug GSTP1-1 Inhibitor, In Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)Azra Raza, Mikkael A. Sekeres, Scott E. Smith et al.|Blood|2010Cited by 2